Harmony Biosciences Holdings, Inc. (HRMY)
| Market Cap | 1.80B |
| Revenue (ttm) | 868.45M |
| Net Income (ttm) | 158.69M |
| Shares Out | 57.87M |
| EPS (ttm) | 2.71 |
| PE Ratio | 11.50 |
| Forward PE | 8.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 509,725 |
| Open | 31.11 |
| Previous Close | 31.05 |
| Day's Range | 30.65 - 31.17 |
| 52-Week Range | 25.52 - 40.87 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 44.11 (+41.51%) |
| Earnings Date | May 7, 2026 |
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in P... [Read more]
Financial Performance
In 2025, HRMY's revenue was $868.45 million, an increase of 21.51% compared to the previous year's $714.73 million. Earnings were $158.69 million, an increase of 9.07%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price target is $44.11, which is an increase of 41.51% from the latest price.
News
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the ...
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company's investigation of EPX-...
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting...
Harmony Biosciences Holdings Transcript: 25th Annual Needham Virtual Healthcare Conference
Strong WAKIX growth and expanded sales teams support a $1B+ revenue target, while new pitolisant formulations and a potent orexin program drive pipeline expansion. Settlements secure exclusivity, and robust cash reserves enable strategic business development across CNS indications.
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Dir...
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual...
Harmony Biosciences to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leeri...
Harmony Biosciences Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw record revenue growth and strong WAKIX adoption, with blockbuster guidance for 2026. Pipeline progress, pediatric approval, and robust cash position support continued expansion, while settlements delay generic entry to 2030 if pediatric exclusivity is granted.
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year ...
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) fo...
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 2...
Harmony Biosciences Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
Momentum into 2026 is driven by WAKIX's blockbuster trajectory, a robust late-stage CNS pipeline, and strong financials. Key milestones include multiple phase III readouts, NDA submissions, and commercial expansion, with significant market opportunity and capital for further growth.
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $...
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Jeffr...
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRM...
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the presentation of initial open-label extension (OLE) data from the company's ongoing Phase ...
Harmony Biosciences Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference
WAKIX continues robust growth with record patient adds, driven by improved execution and payer access. The narcolepsy market is expanding, and WAKIX is well-positioned amid upcoming generic and orexin competition. Next-gen pitolisant and clemizole programs advance, targeting broader indications and improved safety.
Harmony Biosciences Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference
Wakix continues to drive strong patient and revenue growth, supported by new formulations and a robust pipeline including orexin-2 agonists and EPX-100. Organizational expansion and business development are focused on scaling for multiple late-stage programs and commercial opportunities.
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company's investigation of EPX-...
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant gastro-resis...
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced dosing of the first participant in a Phase 1 clinical trial of BP1.15205, an investigational, ...
Harmony Biosciences Holdings Earnings Call Transcript: Q3 2025
Q3 2025 saw record revenue and patient growth, with WAKIX net sales up 29% year-over-year and full-year guidance raised to $845–$865 million. Strong cash generation supports a robust late-stage pipeline, while strategic capital deployment and product differentiation position the company for continued growth.
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX®. Th...
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise d...
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.